Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antoni Ribas

Showing results (31-40 of 467) with videos related to

Pageof 47
Sort By:
Medicina Clinica|April 18, 2002
[Clinical development of antitumoral vaccines]Antoni Ribas, Manuel Ribas-Mundó
Nature Reviews. Clinical Oncology|May 25, 2011
BRAF targeted therapy changes the treatment paradigm in melanomaAntoni Ribas, Keith T Flaherty
Future Oncology (London, England)|December 15, 2010
Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modelingAntoni Ribas, Richard C Koya
Expert Opinion on Biological Therapy|February 19, 2002
Immunotherapy of hepatocellular carcinomaLisa H Butterfield, Antoni Ribas
Clinical Journal of Oncology Nursing|July 25, 2017
Collaborative Care in Melanoma: The Essential Role of the Nurse
John M Kirkwood, Antoni Ribas
Science (New York, N.Y.)|March 24, 2018
Cancer immunotherapy using checkpoint blockadeAntoni Ribas, Jedd D Wolchok
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2014
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockadeAntoni Ribas, Paul C Tumeh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Gauging the Long-Term Benefits of Ipilimumab in MelanomaAntoni Ribas, Keith T Flaherty
Current Opinion in Immunology|January 27, 2015
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?Daniel Sanghoon Shin, Antoni Ribas
Current Opinion in Immunology|April 9, 2013
Combining cancer immunotherapy and targeted therapyAntoni Ribas, Jedd D Wolchok
Pageof 47

Showing results (31-40 of 467) with videos related to

Sort By:
Pageof 47
Medicina Clinica|April 18, 2002
[Clinical development of antitumoral vaccines]Antoni Ribas, Manuel Ribas-Mundó
Nature Reviews. Clinical Oncology|May 25, 2011
BRAF targeted therapy changes the treatment paradigm in melanomaAntoni Ribas, Keith T Flaherty
Future Oncology (London, England)|December 15, 2010
Adoptive cell transfer of T-cell receptor-engineered lymphocytes: lessons from recent modelingAntoni Ribas, Richard C Koya
Expert Opinion on Biological Therapy|February 19, 2002
Immunotherapy of hepatocellular carcinomaLisa H Butterfield, Antoni Ribas
Clinical Journal of Oncology Nursing|July 25, 2017
Collaborative Care in Melanoma: The Essential Role of the Nurse
John M Kirkwood, Antoni Ribas
Science (New York, N.Y.)|March 24, 2018
Cancer immunotherapy using checkpoint blockadeAntoni Ribas, Jedd D Wolchok
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2014
The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockadeAntoni Ribas, Paul C Tumeh
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 11, 2015
Gauging the Long-Term Benefits of Ipilimumab in MelanomaAntoni Ribas, Keith T Flaherty
Current Opinion in Immunology|January 27, 2015
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?Daniel Sanghoon Shin, Antoni Ribas
Current Opinion in Immunology|April 9, 2013
Combining cancer immunotherapy and targeted therapyAntoni Ribas, Jedd D Wolchok
Pageof 47